Targeted Oncology has reported on the FDA’s decision to grant Fast Track designation to suplexa, our non-engineered autologous cellular immunotherapy, for the treatment of patients with MSI-H colorectal cancer.
The article highlights the data from our completed phase 1 SUPLEXA-101 trial that supported the designation, including two responses in patients with MSI-H colorectal cancer treated with suplexa as a monotherapy — one complete response and one partial response, both sustained beyond 80 weeks. It also covers how suplexa is manufactured from a patient’s own peripheral blood mononuclear cells using our proprietary ENLIST platform, without any genetic modification.
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
